European Monitoring Centre
for Drugs and Drug Addiction

EMCDDA/50/18

FINAL MINUTES OF THE FIFTY–EIGHTH MEETING OF THE MANAGEMENT BOARD (13–14 DECEMBER 2018)

13 DECEMBER

Introduction by the Chair

The **Chair, Ms Laura d'Arrigo,** welcomed the participants and informed about the new members on the Management Board. Ms Tiina Drell, Advisor at the Public Health Department of the Ministry of Health, was nominated as member for Estonia. Romania nominated Mr Constantin Negoiţă, Interim Director of the National Anti-Drug Agency, as member.

The Chair welcomed the new members present at the meeting. Ms Jarmila Vedralová, national drug coordinator, from the Secretariat of the Government Council for Drug Policy Coordination, was nominated as member for the Czech Republic. Ms María Azucena Martí, Delegate for the National Plan of Drugs, and Ms Elena Álvarez Martin, Deputy Director for Institutional Relations, represented Spain as member and substitute member respectively. Ms Ruxanda Iliescu, Head of the national focal point, was nominated as substitute member for Romania, and Ms Nadežda Lobodášová, Director of the Drug Coordination and Drug Monitoring Department of the Ministry of Health, was appointed as member for Slovakia.

Ms Marlene Mortler, the German Federal Drug Commissioner, was accompanied by Mr Stephan Brandt from her Office. Ms Amelia Nunnari, from the Department for Anti-Drug Policies, accompanied the delegation from Italy. Ms Ana Sofia Santos, Head of the Department for International Relations of SICAD, accompanied the Portuguese delegation. In the absence of the member and substitute member from Slovenia, Ms Maša Serec represented her country during this meeting. Slovenia gave its proxy vote to France. Bulgaria could not be represented at the meeting and gave its proxy vote to Cyprus. Mr Erdem Koç, Deputy Director of the Counter Narcotics Department, represented Turkey during the meeting.

The European Commission appointed its representatives on the EMCDDA Management Board by a decision of 16 October 2018. Ms Paraskevi Michou, Director-General of Directorate-General Migration and Home Affairs (DG HOME) and Mr Olivier Onidi, Deputy Director-General Director for Security at DG HOME were designated as members. Mr Laurent Muschel, Director for Security at DG HOME, and Ms Floriana Sipala, Head of the 'Organised Crime and Drugs Policy' Unit or Mr Wojciech Kałamarz, Head of the 'Health Determinants and Inequality' Unit at the Directorate-General for Health and Food Safety (DG SANTE) were designated as substitute members. Mr Laurent Muschel, Director for Security at DG HOME, attended the meeting and was accompanied by Ms Edith Hofer, responsible for the coordination with the EMCDDA at the 'Organised Crime and Drugs Policy' Unit of DG HOME, as observer.

The new Executive Secretary of the Pompidou Group of the Council of Europe, Mr Denis Huber, attended the Board meeting. The representative of UNODC was excused.

The Chair welcomed the interpreters, providing simultaneous interpretation from and into French, English, and German. Members could in addition speak Danish, Spanish and Romanian.

The Chair reminded the participants that the Budget and Executive Committee met on 12 December 2018 in order to prepare the Management Board meeting.

Finally, Ms d'Arrigo announced some security measures in case of a fire alarm and evacuation of the building.

1. Adoption of the agenda

EMCDDA/22/18 rev 2
EMCDDA/23/18

The **Chair** suggested adding a decision by the Management Board under agenda item 7.4. concerning the election of the Chair of the Budget Committee.

Ms d'Arrigo further proposed adding under 'Any other business' the request by the Ministry of Internal Affairs of the Republic of Kosovo* for a working arrangement with the EMCDDA and the Portuguese Presidency of the Pompidou Group of the Council of Europe.

Decision: The Management Board adopted the revised agenda of the meeting.

2. Activity reports:

2.1. Report on the activities of the Chair — EMCDDA/24/18

The **Chair** reported about the meeting with the Chair of the Scientific Committee and the Spokesperson of the national focal points (NFPs). She also reported about the ad hoc group meetings for the external evaluation of the EMCDDA which she attended with the Vice-Chair.

2.2. Report from the Budget Committee — EMCDDA/25/18

The **Chair of the Budget Committee** informed the Board members about the discussions held at the last two Budget Committee meetings according to the items on the agenda.

2.3. Report on the external activities of the Director — EMCDDA/26/18

The **Director** briefly reported about his external activities. He highlighted the efforts to strengthen the EMCDDA's collaboration with the Committee on the Environment, Public Health and Food Safety (ENVI) of the European Parliament and the collaboration with the European Commission, in particular DG HOME and DG SANTE. The Director thanked the European Commission for the close collaboration concerning the working arrangements between the EMCDDA and five EU Agencies (Europol, EMA, ECDC, EFSA and ECHA), in accordance with Article 5 b.8 of the EMCDDA founding Regulation, last amended by Regulation (EU) 2017/2101 of 15 November 2017 (which amends the EMCDDA founding regulation to strengthen the role and tasks of the latter for the information exchange, early warning system and risk assessment on new psychoactive substances).

In an event in the margins of the Ministerial Forum of Justice and Home Affairs on 5 October 2018 in Tirana (Albania), the Director initialled the draft working arrangement between the EMCDDA and the Republic of Albania, with the Deputy Minister of Interior and the Deputy Minister of Health and Social Affairs. The Director suggested that the issue of drugs and trafficking should be put on the agenda of a future meeting of the Ministerial Forum.

The Director also stressed his participation on 29 November 2018 in a Round Table on 'Production, trafficking and consumption of drugs: the situation in the various regions of the world' at the International Conference on 'Drugs and Addictions: An Obstacle to Integral Human Development' organised by the Dicastery for Promoting Integral Human Development at the Vatican City in Rome.

The Director thanked the representatives of CY, EE FR and DE for organising his official visits to these Member States after the summer.

3. Presentations by EU Presidencies

3.1. Presentation on the conclusions of the Austrian Presidency

Mr Raphael Bayer summarised the first conclusions of the **AT** Presidency and thanked the Member States for their collaboration.

In terms of drugs policy, the main priorities of the AT Presidency were the preparation for the 2019 CND Ministerial Segment and alternative development, for which the Council adopted conclusions on 6 December 2018. The AT Presidency thanked in particular DE for the substantial input provided in this context. The Horizontal Working Party on Drugs (HDG) started the preparation for a common position for the international scheduling of NPS and addressed the role of Internet/Darknet in the production, marketing and distribution of drugs from two angles. EU dialogues with third countries took place with the USA, the Russian Federation and CELAC countries, and a joint meeting between the HDG and the Civil Society Forum on Drugs was organised on 7 November. The AT Presidency supported information-sharing between the HDG and other Council bodies. The national drug coordinators meeting took place on 8 October 2018 in Vienna.

On behalf of the Management Board, the **Chair** congratulated AT for its efficient and successful Presidency.

3.2. Presentation of the programme for the Romanian Presidency

Ms Ruxanda Iliescu, future Chair of the HDG, thanked the AT Presidency for its excellent work and presented the priorities of the **RO** Presidency.

In terms of drugs policy, the main priorities of the RO Presidency are the preparation of the Ministerial Segment for the 62nd session of the CND in March 2019 and the 2019 review process of the UN global drug policy. They also include the preparation of the ordinary segment of the CND session and the international scheduling of NPS.

The Horizontal Working Party on Drugs will organise EU dialogues with the USA, CELAC and Brazil, and will continue making regular reviews of the implementation of the EU Action Plan on Drugs 2017–20. The RO Presidency will continue supporting information-sharing between the HDG and other Council bodies, in particular COSI. Possible topics for thematic debates are 'Defining the role of the national drug coordinator at EU level', 'The importance of case management in drug addiction care' and 'Ensuring continuity of actions initiated by previous presidencies'. The National Drug Coordinators meeting will take place on 9–10 April 2019 in Bucharest.

On behalf of the Management Board, the **Chair** wished RO good luck for its Presidency, and assured RO of the support from the EMCDDA and the Member States.

4. Points for discussion:

4.1. Key conclusions of the EMCDDA's external evaluation: presentation by the European Commission

The **Chair** thanked the European Commission, and in particular the Unit on Organised Crime and Drugs Policy of DG HOME, for the external evaluation of the EMCDDA. The Chair appreciated the inclusive approach taken by the European Commission during the external evaluation and the results despite the time constraints. Ms d'Arrigo underlined the excellent collaboration between the EMCDDA, in particular Mr Paul Griffiths and Mr Fabian Pereyra, and the European Commission, in particular Ms Edith Hofer, during this exercise.

Mr Laurent Muschel, representative of the European Commission, expressed his personal gratitude to all Management Board members for their participation in the process led by the external consultants between March and October 2018. The European Commission will draft a policy document, which will take into account the reflections of the consultant and the views expressed by the Management Board in December on the main conclusions of the report and how to envisage the way forward. Any possible legislative proposal for a revision of the EMCDDA's mandate might be made by the new Commission after November 2019.

The results of the evaluation are very positive. The EMCDDA is working very well, delivers excellent outputs and has a high reputation at European and international level. Some recommendations for improvements put forward by the consultants concern some issues that can be implemented within the current legal framework: dissemination of EMCDDA outputs, human resources management and activity based management. Other recommendations present several options, such as enhancing the EMCDDA's capacity to monitor drug supply side issues, focusing international cooperation activities on adding value to EMCDDA core objectives, and broadening the scope of the mandate to other types of addictions.

Mr Muschel invited the Management Board members to think creatively about how to reinforce the EMCDDA. Possible ideas could be to give the EMCDDA laboratory capacity, or to task the agency with the organisation of information campaigns or public health alerts on NPS for Member States.

The **Chair of the Scientific Committee** congratulated the Director and the Centre for the positive assessment of its performance over the last six years, which was not self-evident from the start. Ms Bretteville-Jensen also thanked the European Commission and the consultants for the objective, timely and quality work during this evaluation. The inclusion of alcohol or prescription drugs in the tasks of the agency requires thorough reflection, since alcohol concerns a huge area which is very distinct from illicit drugs. From a scientific point of view, the use of alcohol together with illicit drugs is still very important. Any broadening of the EMCDDA's mandate should be accompanied by increased resources. The Chair of the Scientific Committee also pointed out that due to the developments towards legalisation of cannabis in various countries, prevention measures will have to be modified.

FR congratulated all actors involved in the external evaluation, and the EMCDDA for the results. FR clearly supported a broadening of the scope of the EMCDDA to licit substances, as in terms of public health the distinction between licit and illicit is not relevant anymore, and prevention measures – especially for young people – have to address behaviours. In this sense the EMCDDA would become even more useful for public institutions in the Member States.

BE congratulated the EMCDDA Director and his staff for the excellent evaluation, and paid tribute also to the previous Director, Mr Wolfgang Götz for his work during the period under analysis. BE expressed the view that the agency should increase its activities in the area of drug supply, and considered the inclusion of monitoring alcohol as strategically non-advisable, in particular because of difficulties in the resources and methods of data collection by the NFPs in this area.

The **Spokesperson of the Reitox NFPs** welcomed the excellent report, and the references to the Reitox network of NFPs in various parts of the document even if it the network was not evaluated as such. Ms Gremeaux noted the recommendations for improving data collection and developing the drug supply indicators, and referred to the Reitox Development Framework which outlines progress to be implemented in this area in the coming years. She stressed that any change in the EMCDDA's mandate has to be accompanied by funding and support from the Member States to the NFPs.

Mr Wolfgang Götz, representative of the European Parliament, welcomed the very positive evaluation report. He stated that the EMCDDA should explore the opportunity to be fully linked with DG HOME of the European Commission. Mr Götz drew the attention to the fact that the report does not refer to the strategic analysis capacity that the EMCDDA developed over the past years. This unique capacity could be better explored, and would confer more importance to the agency (Europol only has operational analysis). It is also fundamental that the EMCDDA continues to bring together both the health and the law enforcement pillars.

ES informed that the Spanish National Strategy on Addictions (2017-24) addresses illicit drugs, new psychoactive substances, other substances (alcohol, tobacco and medicines) and behavioural addiction. It would be beneficial to speak the same language in Europe with broader national drug policies or strategies.

AT thanked the European Commission and the consultants for an excellent evaluation report, which demonstrates the EMCDDA's added value in the core areas of its work. It would be desirable for the EMCDDA to see its mandate widened to addictive behaviours, to follow the developments in national drug policies in Europe. Nevertheless internal reflections have to take place at the European Commission to assess the implementation of such a revision.

NL congratulated the Director and the Centre for the good results of the evaluation, which confirms the view that the EMCDDA works well. NL also welcomed the reference to the cooperation with the NFPs in the report. It is important to keep examining how the agency can properly implement its current tasks, with appropriate resources. NL agreed that the strength of the agency relies on its work in two areas, health and security.

For the **UK**, the evaluation shows the EMCDDA's added value and its unique position for monitoring the drugs problem across Europe and detecting trends, in particular through the Early Warning System. The responsibilities of Public Health England also span alcohol, drugs, tobacco and gambling. A review on prescription medicines, a significant problem in the US, is on-going in the UK. However the problem is how to set boundaries to public health harms of addictive behaviours. The expertise of the EMCDDA could be diluted without an adequate resourcing.

DE thanked the EMCDDA for its excellent work, which is confirmed by this external evaluation. The added value of the agency is widely recognised, but it is necessary to think about further improvements and ways to face future challenges. The German National Strategy on Drugs and Addiction Policy addresses licit and illicit substances as well as non-substance related addictions such as gambling and online/media addiction. This broad remit can only be addressed with adequate staff, technology and budget. DE stressed the importance of prevention.

PT congratulated the contractor, the European Commission and the EMCDDA for the very good report. The National Plan for Reduction of Addictive Behaviours and Dependencies for 2013–20 addresses a range of areas, including illicit drug use, new psychoactive substances, alcohol, prescribed medicines, doping and gambling. Should the mandate of the EMCDDA be broadened, it has to be implemented gradually, with adequate resources for the centre and the Reitox network. PT also drew the attention to the tendency to modify the legal status of some substances. Should cannabis be legalised all around Europe in the future, would this imply that the EMCDDA within its current mandate will cease collecting and analysing data on cannabis?

DK thanked the Director and the EMCDDA staff, as well as the European Commission, for the evaluation report. The outcome is very positive on the way the Centre operates. The assessment is balanced and nuanced, and provides food for thought for the future. DK expressed some reservations about a possible broadening of the agency's mandate, but also the wish to contribute in a constructive way to the discussions.

WHO congratulated the Director and the Centre for the excellent work as reflected in the report. Concerning alcohol and cannabis use, some alcohol industries have made big investments in cannabis products, so that the limits between the substances will become less clear. Inevitably the EMCDDA's mandate will have to be extended and additional areas for joint work between the EMCDDA and WHO might be defined. WHO suggested clarifying if a possible extension of the agency's mandate concerns the monitoring of trends in legal substance use or broadening the EMCDDA's functions to areas other than monitoring.

The **Pompidou Group of the Council of Europe** congratulated the EMCDDA on its leadership and work, and the European Commission for having conducted the evaluation. Mr Huber informed that the Pompidou Group will start reviewing its mandate and in this context the discussion on the scope of the EMCDDA is of particular interest.

IT thanked the agency and the European Commission, and supported the view that it is necessary to ensure supplementary budget in case of broadening the monitoring scope, and to seek guaranteeing the quality of the work.

The **Director** thanked the interlocutors for the positive feedback, which he shared with his predecessor. He thanked the Chair and Vice-Chair for their participation in the ad hoc group, and DG HOME for its excellent collaboration, in particular Ms Edith Hofer. The support from Mr Paul Griffiths and Mr Fabian Pereyra were extremely useful and he thanked them for their commitment. As stated in the EMCDDA Strategy 2025, the EMCDDA's added value has to be perceived by policymakers and practitioners in planning and delivering policies and programs that contribute to a healthier and more secure Europe. The Director proposed to draft an Action Plan to follow-up on the recommendations made by the external evaluation, adding that some issues are already being addressed.

Mr Laurent Muschel, representative of the European Commission, observed that the different views expressed showed that there was no consensus among Board members concerning an extension of the EMCDDA's mandate to licit substances and/or addictive behaviours. However, there seems to be an agreement on maintaining the two strains of health and security as basis for the agency's work. In case of a widening or deepening of the agency's mandate, additional financial and human resources will be clearly needed, as it was with the case of other JHA Agencies such as Frontex. The fundamental question is if the mandate should be extended or not. Mr Muschel welcomed the proposal from the Director to prepare an Action Plan within the current mandate of the agency.

Concluding, the **Chair** thanked all Management Board members who participated in the discussion. The result of the evaluation, which includes the Reitox network as an integral part of the EMCDDA, was very positive, despite the time constraints. The Chair highlighted that a clear link should be established between the good results and the evolution of resources (human and budgetary), and stressed that the national representatives in the Council should be made aware of the situation. The tendency to wider national drug policies and strategies in the Member States corresponds to scientific evidence. Some reluctance to broaden the EMCDDA's mandate was expressed. The EMCDDA should explore all possibilities to pave the way for the future in view of the next Commission in November 2019. The EMCDDA could also intensify its work in the area of Best practice, especially for prevention. The reputation of the agency, the quality and scientific rigor of its work should remain a priority, and the vision to contribute to a healthier and more secure Europe should be maintained. The Chair encouraged the European Commission to closely work with the EMCDDA to reinforce these two pillars with caution but also with ambition.

5. Points for discussion:

5.1. Multiannual Financial Framework for 2021–27: presentation by the European Commission

Mr Laurent Muschel, representative of the European Commission, informed that the Multiannnual Financial Framework (MFF) for 2021–27 should be adopted in October 2019. The current proposal includes EUR 2,5 Billion for the Security Area for the seven years, and EUR 1.12 Billion for the EU financing to three EU Agencies in this area (EMCDDA, Europol, Cepol) over the same period. The European Commission advised that Ministers of Interior of the EU Member States should actively defend the budget for Agencies at the Council. The European Commission will report back on the state of play concerning the negotiations at the Management Board meeting of June 2019.

The **Director** thanked the European Commission for the MFF proposal. He stressed that it was extremely important that awareness was raised among Ministers of Interior at national level about the budget situation for the EMCDDA in the coming years, even if the Council's priorities lie clearly on security and migration.

The **Chair** congratulated the Commission for the ambitious proposal. Despite the current EU priorities, it is necessary to seize the opportunity for reflecting on how best to address the issue of drugs at European level.

6. Points for decision/adoption by the Management Board:

6.1. Programming Document for 2019–21, including work programme for 2019 EMCDDA/28/18

The **Director** reminded that the EMCDDA Multi-annual Programming Document (PD) is the first PD which is fully aligned with the EMCDDA Strategy 2025, in terms of structure (three main areas: Health, Security, and Business drivers) and content. The Director thanked all the Heads of Units, the Administration, the Executive Office, and in particular Ms Narcisa Murgea, Strategic planning and corporate performance manager, for the excellent work.

The Director highlighted some key activities and outputs foreseen for 2019. One of the highlights will be starting the review of the European Drug Report package, to maximise the benefit from investment and reaching out to customers. The three-year EU4 Monitoring Drugs project will start in January 2019. In the Health area, support to the 2019 ESPAD data collection will be implemented with limited means (this activity will not become a level 1 priority as suggested in the opinion of the European Commission). In the Security area, the next edition of the EMCDDA-Europol EU Drug markets Report will be launched in 2019. In terms of Business drivers, the EMCDDA will draft an Action Plan to follow up on the final report of the EMCDDA's external evaluation, and initiate a strategic analysis of consequences of potential future changes to the EMCDDA Regulation. A project aiming at improving the understanding of the needs of the agency's customers will be implemented.

In addition, the Director noted that the work programme for 2019 had been adapted to the budgetary constraints for the next year. The amount for staff-related expenditure increased by about EUR 600 000 in accordance with the applicable Staff Regulations (staff's automatic progression to the next step and annual adjustment of the EU staff's remuneration, including the variable of the applicable weighting factor) in comparison with 2018. Also, the cost of the lease of the EMCDDA premises will increase by about EUR 300 000 in 2019, and the additional amount of EUR 310 000 requested for the coordination and the development of the activities of the European School Survey Project on Alcohol and Other Drugs (ESPAD) in 2019 was not included in the EU subsidy to the EMCDDA. It was therefore necessary to take measures to match the available budget resources (reduction of available resources for other budget items by more than EUR 1 000 000, nearly 10% of the EU subsidy to the EMCDDA in 2019) and needs. The Director explained some of the measures taken for 2019: no new recruitment, no new trainees, reduction of staff's training and promotion/reclassification, reduction of building-related expenditure, and ICT equipment and services. Transversal cuts have also been operated in the expenditure for operational activities, while keeping the EMCDDA Reitox co-financing at the same level as 2018. A note was circulated on the measures taken for the preparation of the EMCDDA 2019 budget and which are relevant for the definition of the EMCDDA 2020 preliminary draft budget. The Director showed a graph with the budgetary evolution of the EMCDDA from 2013 to 2020, which shows that Title 3 (operations) of the budget will correspond in 2019 to only 9% of the total budget of the agency.

The Director expressed concerns about the structural problem of the evolution of staff-related expenditure obliging the agency to reduce its budget appropriations for operational activities, thus creating a critical situation for the next years. The EMCDDA will have to envisage changes to its Business Model, about which the Director will inform the Management Board in December 2019. The Director stressed the paradox of the EMCDDA's budgetary situation while the agency received the best external evaluation ever.

The **Chair of the Budget Committee** noted that the Budget Committee had suggested drafting a cover note to detail the efforts undertaken to adapt to the budgetary constraints for 2019, and thanked the Director for the rapid response.

Mr Laurent Muschel, representative of the European Commission, congratulated the Director on the quality of the PD for 2019–21 and on his presentation. The European Commission issued a positive formal opinion in September, of which most suggestions have been taken on board and fully supports its adoption.

Mr Wolfgang Götz, representative of the European Parliament, emphasised that the agency had the same budgetary resources than ten years ago, but with less staff members. The EMCDDA faces a need for additional resources since the budget for operational activities is under high pressure. The European Commission decided in 2013 that no additional budget should be allocated to 'cruising speed' Agencies with no new tasks, but did not

take inflation into account. The European Commission should reflect about this model (DG HOME could launch the initiative to discuss this issue with DG BUDG).

The **Chair** thanked the Director and his staff for the quality of the Programming Document, as well as of the cover note. Ms d'Arrigo stressed the link between the results of the external evaluation and the budgetary envelope which does not increase in real terms.

Decision: The Management Board adopted the EMCDDA's Programming Document for 2019–21, which includes the work programme for 2019.

6.2. Budget for 2019 — EMCDDA/29/18

The **Chair of the Budget Committee** summarised the main figures of the EMCDDA budget for 2019.

In line with the decision of the EU Budgetary Authority on the adoption of the EU budget for 2019, the EU 2019 subsidy to the EMCDDA amounts to EUR 15 455 600. It includes the resources required to meet the additional 2018 tasks relating to the monitoring of New Psychoactive Substances (NPS). The EMCDDA budget for 2019 also includes the contributions by Norway and by Turkey. Pursuant to the agreement in force between the EMCDDA and the Lisbon Port Authority (LPA), the 2019 cost for the lease of the EMCDDA premises is expected to be reduced by about EUR 482 400 compared to 2015 (this corresponding to an increase of the rental costs by EUR 284 268 compared to 2018). The Chair of the Budget Committee recalled that as from 1 May 2020 the EMCDDA will have to pay the full rent for the lease of its EMCDDA premises. The appropriations for the EMCDDA co-financing to the Reitox national focal points remain the same as in 2018. The withdrawal of the UK will not have any impact on the amount of the EU subsidy for the EMCDDA in 2019.

The Management Board will be requested to adopt an amending budget no. 1 to the 2019 budget to enter the revenue for the EMCDDA-IPA 7 project, which should start on 1 July 2019.

The Budget Committee recommends to the Management Board to adopt the EMCDDA budget for 2019.

Decision: The Management Board adopted the EMCDDA budget for 2019.

6.3. Preliminary draft Programming Document for 2020–22, including work programme for 2020 — EMCDDA/30/18

The **Director** briefly presented the preliminary draft PD covering the period 2020–22. The Consultation draft PD will be submitted by 31 January 2019 to the European Commission and the EMCDDA Scientific Committee for formal opinion. The Management Board will receive a copy of this document.

In 2020 the EMCDDA will celebrate 25 years of drugs monitoring. A mid-term assessment of the EMCDDA Strategy, guided by the Roadmap 2020, will be presented to the Management Board in December 2020.

Decision: The Management Board adopted the preliminary draft Programming Document for 2020–22, which includes the preliminary draft work programme for 2020, with the abstention of the European Commission for institutional reasons.

6.4. Preliminary draft budget for 2020 — EMCDDA/31/18

The **Chair of the Budget Committee** presented the main features of the EMCDDA preliminary draft budget (PDB) for 2020. The financial statement accompanying Regulation (EU) 2017/2101 of 15 November 2017 (which amends the EMCDDA founding regulation to strengthen the role and tasks of the latter for the information exchange, early warning system and risk assessment on new psychoactive substances) envisages an amount of EUR 15 588 600 for the EU 2020 subsidy to the EMCDDA. It also includes an additional amount of EUR 310 000 required to cope with the 2020 additional needs and workload entailed by the increased role of the EMCDDA for the coordination and the development of ESPAD.

Pursuant to the agreement in force between the EMCDDA and the Lisbon Port Authority (LPA), the 2020 annual cost for the lease of the EMCDDA premises is expected to be reduced by about EUR 116 200 compared to 2015 (this corresponding to an increase of the rental costs by approximately EUR 400 000 compared to 2019).

The Chair reminded that the elements of the EMCDDA PDB for 2020 have been defined without prejudice to the effect and constraints that may result for the EMCDDA budget from the expected exit of the United Kingdom from the European Union in March 2019 (which will depend on the outcome of the ongoing process aimed at defining the conditions of this exit).

The Budget Committee recommends to the Management Board to adopt the EMCDDA preliminary budget for 2020.

Decision: The Management Board adopted the preliminary draft budget for 2020, with the abstention of the European Commission for institutional reasons.

15 DECEMBER

7. Points for decision/adoption by the Management Board:

The **Chair** announced the voting arrangements. The elections took place by secret vote, for a total of 32 votes, the two thirds majority being 21 votes. BU gave its proxy vote to CY and SI to FR.

7.1. Election of the Chair of the Management Board (restricted session) EMCDDA/32/18

The current Chair, Ms Laura d'Arrigo (FR), was elected on 3 December 2015 for a three-year mandate (2016–18). Her mandate ends on 31 December 2018 and can be renewed. The Chair announced that she was candidate for being renewed as Chair. The Vice-Chair was assisted by Mr João Goulão and Mr Laurent Muschel for counting the votes.

Decision: The Management Board elected Ms Laura d'Arrigo in the first voting round at unanimity for a second mandate as Chair of the Management Board from 1 January 2019 to 31 December 2021.

Ms d'Arrigo thanked the Management Board members for their trust and declared her commitment to collaborate in a constructive way with all members during her mandate.

7.2. Election of the Vice-Chair of the Management Board (restricted session) EMCDDA/33/18

The current Vice-Chair, Mr Franz Pietsch (AT), was elected on 3 December 2015 for a three-year mandate (2016–18). His mandate ends on 31 December 2018 and can be renewed. The Chair announced that Mr Franz Pietsch (AT) was candidate for being renewed as Vice-Chair. The Chair was assisted by Mr João Goulão and Mr Laurent Muschel counting the votes.

Decision: The Management Board elected Mr Franz Pietsch in the first voting round by 29 votes in favour, 3 votes against and no abstentions for a second mandate as Vice-Chair of the Management Board from 1 January 2019 to 31 December 2021.

Mr Franz Pietsch thanked the Management Board members for his election and expressed his commitment for a close collaboration with the Chair and all Management Board members.

7.3. Election of one Executive Committee member (restricted session) EMCDDA/34/18

The **Chair** announced that one application was submitted for membership in the Executive Committee from Mr Lars Petersen (DK). The Chair was assisted by Mr João Goulão and Mr Laurent Muschel counting the votes.

Decision: The Management Board elected Mr Lars Petersen (DK) as Executive Committee member in the first voting round at unanimity for a mandate from 1 January 2019 to 31 December 2021.

Mr Petersen thanked the Management Board members for their support.

7.4. Election of one Budget Committee member (restricted session) EMCDDA/35/18

The **Chair** announced that one application was submitted for membership in the Budget Committee: Mr Claude Gillard (BE). The Chair was assisted by Mr João Goulão and Mr Laurent Muschel counting the votes.

Decision: The Management Board elected Mr Claude Gillard (BE) as Budget Committee member in the first voting round at unanimity for a mandate from 1 January 2019 to 31 December 2021. The Management Board also elected at unanimity Mr Claude Gillard as Chair of the Budget Committee for the same period.

Mr Claude Gillard thanked the Management Board members for their support.

FI thanked the elected Chair and Vice-Chair of the Management Board, as well as the member of the Executive Committee and the Chair of the Budget Committee for their time and contribution to the common cause.

7.5. Working arrangement between the EMCDDA and Albania — EMCDDA/36/18

At its meeting in June 2018, the Management Board mandated the EMCDDA Director to negotiate a formal cooperation agreement between the EMCDDA and the Ministry of Interior and Ministry of Health and Social Protection of the Republic of Albania. The EMCDDA and the two Ministries, in close liaison with DG HOME of the European Commission, agreed on a final draft which was submitted to the European Commission for opinion on 20 September 2018. The Director informed that the positive opinion of the European Commission was submitted recently.

Decision: The Management Board took full note of and agreed with the Working Arrangement between the EMCDDA and the Ministry of Interior and Ministry of Health and Social Protection of the Republic of Albania, and hereby mandated the Director to sign the Working Arrangement on a date and place to be jointly decided between the Deputy Ministers of Interior and Health and Social Protection and the EMCDDA Director.

7.6. Working arrangement between the EMCDDA and Ukraine — EMCDDA/37/18

In January 2010, the signature of the Memorandum of Understanding (MoU) between the EMCDDA and the Ukrainian Ministry of Health provided a framework for cooperation between the EMCDDA and the Ukrainian Monitoring and Medical Centre on Drugs and Alcohol. This institution was replaced in February 2018 by a new the State Agency called 'The Centre for Mental Health and Monitoring of Drugs and Alcohol of the Ministry of Health of Ukraine'. This institutional change led the Acting Minister of Health of Ukraine, Ms Ulana Suprun in July 2018 to formally request the EMCDDA to renegotiate the MoU between the Ministry of Health of Ukraine and the EMCDDA. The Director informed DG HOME of the European Commission, which clarified that the procedure foreseen by the EMCDDA Regulation should be followed.

Decision: The Management Board mandated the Director to negotiate a Working Arrangement with the Ministry of Health of Ukraine.

7.7. Annual appraisal of the Director: designation of the reporting officers — EMCDDA/38/18

Decision: As proposed by the Executive Committee, the Management Board designated as the reporting officers of the EMCDDA Director the newly elected Vice-Chairperson of the EMCDDA Management Board and Mr Olivier Onidi, representative of the European Commission in the latter. The Management Board further designated as the appeal assessor the newly elected Chairperson of the EMCDDA Management Board.

7.8. Establishment of EMCDDA list of experts to extend the Scientific Committee for the purpose of Risk Assessments — EMCDDA/39/18

Ms Anne Line Bretteville-Jensen, Chair of the Scientific Committee, decided not to attend the meeting for this discussion due to a possible risk of conflict of interest.

Decision: The Managements Board adopted the proposed revision of its Rules of Procedure. The Board confirmed and extended until 31 December 2019 the validity of the last panel of experts that was set up in accordance with Article 6.2. of Council Decision 2005/387/JHA. The Management Board endorsed the draft call for expression of interest for the implementation of the procedure established for the Management Board's approval of the list of experts for the 'extended' Scientific Committee, as well as call for expression of interest in membership of the Scientific Committee for the mandate 2020–22.

7.9. Assessment of the implementation of the EMCDDA Policy for the prevention and management of conflicts of interest for Management Board members, substitutes and observers **EMCDDA/41/18**

The **Chair** announced that all declarations of conflicts of interest have been submitted by the members, substitutes and observers of the Management Board until 7 December 2018 and thanked all for their efforts.

The **Director** stressed that up to that date there are no existing conflicts of interest. Potential risks will be addressed by the Management Board through the mitigating measures as described in the EMCDDA relevant Policy.

Decision: The Management Board took note of the outcome of the screening conducted by the EMCDDA Director that has revealed that for the moment there is no conflict of interest. However, in the future one cannot exclude that a risk of conflict of interest may emerge. Such cases will be addressed by the Management Board through the existing mitigating measures.

8. Points for discussion

8.1. Developments in cannabis policies

The **Scientific Director** provided an update concerning latest developments in cannabis policies to contextualise the discussion. The EU Action Plan on Drugs 2017–2020 asks the EMCDDA to provide an update of the 2017 overview of cannabis legislation in the EU as well as continue to monitor and report on cannabis legislations at national level and in third countries. The EMCDDA is producing a set of interlinked products and services that seek to explore in an objective and neutral manner some of the complex issues that exist in this area. The aim is to provide an overview of evidence and current practice for those with an interest in the area, to inform debate and not to advocate for any particular policy perspective. Examples are the user friendly Drug Policy News service, and a recent technical meeting on Low-THC Cannabis.

Mr Paul Griffiths presented some elements of the EMCDDA report on 'Medical use of cannabis and cannabinoids' which was launched on 4 December 2018. The report aims at clarifying the conceptual framework and the existing evidence of effectiveness.

The **Chair** invited several delegations to share recent developments in cannabis policies.

LU passed a law on 20 July 2018 amending the law of 19 February 1973 regarding the sale of medical substances and the fight against drug addiction, allowing legal access to cannabis for medical purposes, which was published one month later. The definition of 'cannabis for medical purposes' and the pathologies for which it should be used are enshrined in the law. Six products are authorised, and may be prescribed by any trained doctor but may only be dispensed from hospital pharmacies. The first delivery of imported cannabis will take place in December and first prescription and dispensing of cannabis to patients probably at the beginning of 2019. Cannabis for medical purposes will not be produced in LU but products will be imported from countries authorizing such production and distribution (Canada, Germany).Two years after the legalization of cannabis for medical purposes an evaluation will be carried out, which will also examine the need to revised the number and type of pathologies.

Furthermore, the new Government took up the coalition agreement for 2018–23 in December, which stated that the legislation on recreational cannabis will be developed in next 5 years. This is viewed by the Vice Prime Minister, who is also the Minister of Health and of the Economy, as a priority. A chain of production needs to be established under the control of the State to guarantee the quality of the product, and national sales should be carefully regulated. Proceeds from the sale of cannabis will be invested primarily in prevention, awareness and care in the area of dependence. Solutions have to be found to this new proposal, and LU will be grateful to receive any support, in particular concerning legal questions, from the EMCDDA. At the question on the conformity with the International Conventions, the representative of LU said this aspect has to be clarified.

Mr Tomas Zabransky, representative of the European Parliament, wondered how to prevent that any cannabis plants cultivated at home are stolen by minors.

In **DK** discussions on decriminalisation or legalisation of cannabis for recreational use have been recurrent for some time but motions in this sense have been dismissed by the government and a majority in the Parliament so far. Concerning the use of cannabis for medical purposes, the Danish authorities organised a fact-finding visit to the Netherlands, as a political agreement was reached in November 2016 to establish a four-year pilot scheme to

end in 2021. From 1 January 2018 cultivation of cannabis by companies for medical use was allowed and by the end of October 2018, three firms were licensed to import cannabis for medical purposes. The products are dispensed in pharmacies for four indications. The Danish Agency for Medicines delivers the authorisations for the import and cultivation of cannabis for this purpose. Regarding Low-THC cannabis products, the Danish authorities were in contact with the EMCDDA and its Legal Correspondents network to compare the situation with other countries, and thanked EMCDDA for its assistance. As a result, a new level of 0,2% of THC has been set as a limit for cannabis-based products, though food and medicines laws will continue to apply.

The **Chair of the Scientific Committee** thanked the EMCDDA for being forward looking with a series of studies that are very helpful for the Member States in a changing situation in Europe. It is important to examine which initiatives are possible at national level to increase research on this issue. Some indicators such as the General Population Surveys will have to include new ways of cannabis consumption, in order to assess the effectiveness of national responses.

WHO agreed that Member States should consider very carefully changes towards legalisation of cannabis for recreational use, as the international industry is already marketing to influence public attitudes to legislation; like with alcohol, industry-friendly laws might have considerable public health consequences.

FR underlined the increasing complexity of cannabis use and the importance of clarifying the concepts. In France cannabis is regularly consumed by 700 000 persons for recreational use, which is less than alcohol or tobacco. Cannabis use among 17-year-olds continues high, even if it decreased. Young French people have a very positive image of cannabis, but evidence shows health consequences for brain maturation of young people. Penalties should be adjusted to give a rapid fine of 200 Euros, saving police time to not process cases which would rarely receive a prison sentence before. Data on the economic and social impact revealed that about 100 000 young people are involved in drug trafficking in France. The debates are not sufficiently based on scientific evidence, it is necessary to take time for reflection and be cautious with the influencers and opinions of very powerful lobbies; industry is supporting advocacy organisations.

In **AT** the law referring to medical use of cannabis was already changed in 2007. In December 2018, the Ministry issued a clarification regarding THC and CBD in cannabis-based products; these novel foods would now require permission to be sold, and the ministry has not received any applications for such permission. In a national investigation of products openly sold that claimed to contain no more than 0.3 % THC, half of those products contained more, and so they shall be prosecuted for drug supply.

In **NL** cannabis for medical use is prescribed by medical doctors for a specific group of patients. The supply and production of medicinal cannabis to pharmacies and scientific institutions is the responsibility of the Office of Medicinal Cannabis set up in 2000. Home cultivation of cannabis, for any purpose, is prohibited. The Dutch drugs policy allows cannabis sale for recreational use under strict conditions in 573 coffee shops located in about 100 municipalities. An experiment started in October 2017 to legalise the cannabis supply to the coffee shops in order to enforce quality control, but at the time advocating for more prevention. The consultation will end in December and a debate will be held in the Parliament and the Senate around mid-January 2019. A new legislation might be approved after the summer. The Dutch government is trying to balance organised crime control with separation of the markets, and will be transparent about the progress and results of the experiment. Therefore during the experiment all relevant documents will be translated into English and shared on the website: https://www.government.nl/topics/drugs/controlled-cannabis-supply-chain-experiment

PL wondered if the proposals in LU and NL were not a violation of the International Drug Control Conventions, and what signal may be sent to other countries (in or out of EU) that 'small' violations of (other) international laws were acceptable. It is important to be very cautious with the terms and concepts used, in particular in view of the next CND.

PT reminded that it faced the same discussions when drugs were decriminalised, but had more recently been described as a model of best practice; while the laws appeared sometimes to be carved in stone, countries may still act within the spirit of the Conventions. Cannabis was originally banned as it was 'bad' and dangerous yet now it is being used as medicine. Mr Goulão thanked the Chair for having proposed a discussion on this issue, and the EMCDDA for its contributions. PT recently passed a law to allow for a new legislation concerning cannabis for medicinal use. It is important to be clear in the terms used, and so EMCDDA will still have a role in providing objective scientific information, even if countries decide to legalise it.

DE stressed that cannabis is not harmless, in particular in terms of brain development of minors and young adults. In DE increased efforts are undertaken for prevention measures. The developments in LU and NL regarding the recreational use of cannabis are closely observed. Cannabis for medical use has been allowed since 2017. Data on prescribed cannabis are being collected to facilitate a cost-benefit-analysis by 2022.

In **ES** cannabis use is also a major discussion, as 11% of adults use cannabis regularly per year. Often the terms legalisation and decriminalisation are confused. In ES, consumption and minor possession is only an offence if in a public place, as the national constitution aims to protect public health.

The **Chair** thanked all the participants for their interventions. Ms d'Arrigo observed that views and evidence may evolve over time, in particular as regards medicinal research, and this must be taken into account. She stressed the importance to share experience in this complex area, and the EMCDDA's crucial role to inform the debate with evidence, to monitor the developments and clarify concepts. The discussion showed that different approaches exist in the Member States concerning cannabis, in the way they already exist for heroin and morphine (both derived from opium). The issue could be followed up at a future Management Board meeting.

9. Points for information:

9.1. Implementation of the EMCDDA Strategy 2025 — EMCDDA/42/18

The **Director** reminded that the Management Board adopted the EMCDDA Strategy 2025, with a Roadmap for 2016–20, in December 2016. The Board then adopted a new organisational structure in 2017, a new head was recruited for the 'Public Health' Unit, training was organised for the management and work started to be carried out in the area of organisational design to evolve into a more dynamic, proactive and service-oriented organisation in line with the values and objectives set out in the EMCDDA Strategy. In 2018, the programming document for 2019–21 was aligned for the first time with the EMCDDA Strategy 2025, and the EMCDDA was subject to an external evaluation. Adjustments in the organisational design were continued, with the support of an external consultant, and a staff engagement survey was conducted. Furthermore, the EMCDDA started implementing a Project Management Programme initiative based on the PM2 methodology, through several activities, such as training 44 staff members by the end of 2018.

9.2. Overview on the implementation of the key epidemiological indicators in Europe — EMCDDA/43/18

The **Director** underlined the importance of the triennial assessment of the implementation of the key epidemiological indicators in Europe, in dialogue with the Member States, Norway and Turkey.

The **Chair** noted that all countries had received an individual assessment from the EMCDDA, and encouraged the representatives on the Management Board to discuss possible difficulties with the respective NFPs.

9.3. Update on the implementation of outstanding IAS recommendations — EMCDDA/44/18

The **Director** informed the Management Board about the implementation of the recommendations made by the Internal Audit Service (IAS) of the EC further to audits conducted in 2013 (Budgeting and Monitoring within the EMCDDA), 2015 (IT Project Management in the EMCDDA) and 2017 (Management of data collection).

One of the components contained in a recommendation from the 2015 IAS audit, the Enterprise Architecture Management Framework at the EMCDDA, is being implemented. Its practical adoption is expected to start before mid-December. This recommendation will be sent for review to the IAS by the end of 2018, duly supported by the documentation required to justify its closure. The Director pointed out that the current state of implementation shows an acceptable result considering the EMCDDA's size and resources.

Mr Laurent Muschel, representative of the European Commission, emphasised that the EMCDDA should implement all the outstanding recommendations from the IAS.

The **Chair** thanked the EMCDDA Director for his commitment to follow up on these issues.

9.4. EMCDDA pilot initiative to promote HCV testing in drug treatment settings — EMCDDA/45/18

The **Chair** welcomed this important initiative, which corresponds to a priority of WHO and other international agencies.

9.5. EMCDDA Chairmanship of the EU–ANSA network **EMCDDA/46/18**

The **Director** thanked in particular the Scientific Director, Mr Paul Griffiths, and Ms Maria Moreira for their involvement during the year with the EU Agencies Network on Scientific Advice (EU–ANSA).

The **Chair** thanked the EMCDDA for having ensured the Presidency of this network.

9.6. Cooperation with non-EU countries, international organisations and other EU Agencies: recent developments **EMCDDA/47/18**

The **Director** highlighted some of the recent developments in the implementation of the international cooperation strategy with third countries, according to the existing priorities, as well as the cooperation with international organisations and EU agencies. The Director informed that he signed the contract with the EC for the EU4 Monitoring Drugs project which will start on 1 January 2019.

The **Chair** thanked the EMCDDA for the useful report. Ms d'Arrigo reminded about the role of the EU in the data reporting mechanisms of the UNODC, which has been underlined by the external evaluation. The possibility for the EMCDDA to report on behalf of the EU Member States should be further discussed. She also reminded about the ongoing discussions on the Annual Reporting Questionnaire (ARQ) and the EU position insisting on the fact that those discussions on strengthening and streamlining the ARQ have to remain technical, and that the EMCDDA should contribute on the basis of the existing EU evidence-based model.

Mr Wolfgang Götz, representative of the European Parliament, stressed that the issue of the double reporting with the ARQ has been discussed in the EMCDDA Management since the beginning of the agency, without conclusions, partly because some Member States have legal obligations to report to UNODC.

9.7. Second European Conference on addictive behaviours and dependencies (Lisbon, 23–25 October 2019): presentation by the Portuguese delegation **EMCDDA/48/18**

PT provided information about the third European Addiction Conference to the Management Board members. The Conference will take place on 23–25 October 2019 and is organised by the Portuguese SICAD (Serviço de Intervenção em Comportamentos Aditivos e Dependências – General Directorate for Intervention on Addictive Behaviours and Dependencies), the journal Addiction (of the Society for the Study of Addiction), the EMCDDA and ISAJE (International Society of Addiction Journal Editors). The deadline for submitting abstracts is 31 January 2019, and Management Board members will be able to participate in the conference by benefiting from a waiving of the registration fee.

The **Chair** thanked Portugal for its commitment and the EMCDDA for its contribution to this important event.

9.8. Information on procurements for non-administrative activities of an estimated value greater than EUR 60 000 to implement the 2018 work programme **EMCDDA/49/18**

No comments were made to the document.

10. Any other business

- Request from Kosovo*

The **Director** informed that informed that the Republic of Kosovo* sent an official request for a working arrangement with the EMCDDA on 29 November 2018. The Executive Committee advised that the Management Board should be requested to give the Director the mandate to negotiate a working arrangement with Kosovo* at the meeting in June 2019. The Director further informed that other Western Balkan countries will send similar requests in the next future and will keep the Management Board updated.

- Portuguese Presidency of the Pompidou Group of the Council of Europe

PT informed that Portugal has been elected during the last Ministerial Conference of the Pompidou Group of the Council of Europe take over the Presidency in January 2019 for the next four years, with PL as Vice-President. Mr João Goulão thanked Norway for its successful Presidency.

The **Chair** thanked the Director and all the EMCDDA staff for the preparation of the meeting, and the Board members for their contributions. The Chair also expressed her special thanks to the interpreters for their work.

The next meeting will take place on 27–28 June 2019.

Laura d'Arrigo
Chair of the Management Board

Annexes:
I List of participants
II List of decisions and conclusions
III List of action points

Copy: Members, substitutes and observers of the Management Board

ANNEX I

58th meeting of the EMCDDA Management Board

Lisbon, 13–14 December 2018

LIST OF PARTICIPANTS

Belgium	Mr Claude GILLARD
Czech Republic	Ms Jarmila VEDRALOVÁ
Denmark	Mr Lars PETERSEN
Germany	Ms Marlene MORTLER
	Mr Stephan BRANDT
Greece	Mr Gerasimos PAPANASTASATOS
Spain	Ms María Azucena MARTÍ PALACIOS
	Ms Elena ÁLVAREZ MARTIN
France	Ms Laura d'ARRIGO
	Mr Nicolas PRISSE
Croatia	Mr Željko PETKOVIĆ
Italy	Ms Maria CONTENTO
	Ms Elisabetta SIMEONI
	Ms Amelia NUNNARI
Cyprus	Mr Stelios SERGIDES
Latvia	Mr Dzintars MOZGIS
Lithuania	Ms Inga JUOZAPAVIČIENĖ
Luxembourg	Mr Xavier POOS
Hungary	Ms Ibolya CSÁKÓ
The Netherlands	Mr Victor SANNES
Austria	Mr Franz PIETSCH
	Mr Raphael BAYER
Poland	Mr Piotr JABŁÓNSKI

Portugal	Mr João GOULÃO
	Mr Manuel CARDOSO
	Ms Ana Sofia SANTOS
Romania	Ms Ruxanda ILIESCU
Slovenia	Ms Maša SEREC
Slovakia	Ms Nadežda LOBODÁŠOVÁ
	Ms Eva DEBNÁROVÁ
Finland	Ms Elina KOTOVIRTA
Sweden	Mr Johan CARLSON
United Kingdom	Ms Rosanna O'CONNOR
Norway	Ms Lilly Sofie OTTESEN
Turkey	Mr Erdem KOÇ
EUROPEAN COMMISSION	Mr Laurent MUSCHEL (DG HOME)
	Ms Edith HOFER (DG HOME)
EUROPEAN PARLIAMENT	Mr Wolfgang GÖTZ
	Mr Tomas ZABRANSKY
WHO	Ms Carina FERREIRA BORGES
POMPIDOU GROUP	Mr Denis HUBER
SCIENTIFIC COMMITTEE	Ms Anne Line BRETTEVILLE-JENSEN
REITOX	Ms Lies GREMEAUX
EMCDDA	Mr Alexis GOOSDEEL
	Mr Fabian PEREYRA
	Ms Monika BLUM

ANNEX II

LIST OF DECISIONS AND CONCLUSIONS

1. Adoption of the agenda **EMCDDA/22/18 rev 2**

The Management Board adopted the revised agenda of the meeting.

6. Points for decision/adoption by the Management Board:

6.1. Programming Document for 2019–21, including work programme for 2019 **EMCDDA/28/18**

The Management Board adopted the EMCDDA's Programming Document for 2019–21, which includes the work programme for 2019.

6.2. Budget for 2019 **EMCDDA/29/18**

The Management Board adopted the EMCDDA budget for 2019.

6.3. Preliminary draft Programming Document for 2020–22, including work programme for 2020 **EMCDDA/30/18**

The Management Board adopted the preliminary draft Programming Document for 2020–22, which includes the preliminary draft work programme for 2020, with the abstention of the European Commission for institutional reasons.

6.4. Preliminary draft budget for 2020 **EMCDDA/31/18**

The Management Board adopted the preliminary draft budget for 2020, with the abstention of the European Commission for institutional reasons.

7. Points for decision/adoption by the Management Board:

7.1. Election of the Chair of the Management Board (restricted session) **EMCDDA/32/18**

The Management Board elected Ms Laura d'Arrigo in the first voting round at unanimity for a second mandate as Chair of the Management Board from 1 January 2019 to 31 December 2021.

7.2. Election of the Vice-Chair of the Management Board (restricted session) **EMCDDA/33/18**

The Management Board elected Mr Franz Pietsch in the first voting round by 29 votes in favour, 3 votes against and no abstentions for a second mandate as Vice-Chair of the Management Board from 1 January 2019 to 31 December 2021.

7.3. Election of one Executive Committee member (restricted session) **EMCDDA/34/18**

The Management Board elected Mr Lars Petersen (DK) as Executive Committee member in the first voting round at unanimity for a mandate from 1 January 2019 to 31 December 2021.

7.4. Election of one Budget Committee member (restricted session) **EMCDDA/35/18**

The Management Board elected Mr Claude Gillard (BE) as Budget Committee member in the first voting round at unanimity for a mandate from 1 January 2019 to 31 December 2021. The Management Board also elected at unanimity Mr Claude Gillard as Chair of the Budget Committee for the same period.

7.5. Working arrangement between the EMCDDA and Albania **EMCDDA/36/18**

The Management Board took full note of and agreed with the Working Arrangement between the EMCDDA and the Ministry of Interior and Ministry of Health and Social Protection of the Republic of Albania, and hereby mandated the Director to sign the Working Arrangement on a date and place to be jointly decided between the Deputy Ministers of Interior and Health and Social Protection and the EMCDDA Director.

7.6. Working arrangement between the EMCDDA and Ukraine **EMCDDA/37/18**

The Management Board mandated the Director to negotiate a Working Arrangement with the Ministry of Health of Ukraine.

7.7. Annual appraisal of the Director: designation of the reporting officers **EMCDDA/38/18**

As proposed by the Executive Committee, the Management Board designated as the reporting officers of the EMCDDA Director the newly elected Vice-Chairperson of the EMCDDA Management Board and Mr Olivier Onidi, representative of the European Commission in the latter. The Management Board further designated as the appeal assessor the newly elected Chairperson of the EMCDDA Management Board.

7.8. Establishment of EMCDDA list of experts to extend the Scientific Committee for the purpose of Risk Assessments **EMCDDA/39/18**

The Managements Board adopted the proposed revision of its Rules of Procedure. The Board confirmed and extended until 31 December 2019 the validity of the last panel of experts that was set up in accordance with Article 6.2. of Council Decision 2005/387/JHA. The Management Board endorsed the draft call for expression of interest for the implementation of the procedure established for the Management Board's approval of the list of experts for the 'extended' Scientific Committee, as well as call for expression of interest in membership of the Scientific Committee for the mandate 2020–22.

7.9. Assessment of the implementation of the EMCDDA Policy for the prevention and management of conflicts of interest for Management Board members, substitutes and observers **EMCDDA/41/18**

The Management Board took note of the outcome of the screening conducted by the EMCDDA Director that has revealed that for the moment there is no conflict of interest. However, in the future one cannot exclude that a risk of conflict of interest may emerge. Such cases will be addressed by the Management Board through the existing mitigating measures.

8. Any other business

The next meeting will take place on 27–28 June 2019.

ANNEX III

LIST OF ACTION POINTS

Agenda point	Action to take	Responsable	Date
4.1.	Draft an Action Plan to follow-up on the recommendations made by the external evaluation	EMCDDA	June 2019
5.1.	Report to MB on Multiannnual Financial Framework (MFF) for 2021–27	EC	June 2019
6.1.	Prepare options for changes to the EMCDDA's Business Model	EMCDDA	December 2019
7.5.	Signature of the Working Arrangement between the EMCDDA and the Ministry of Interior and Ministry of Health and Social Protection of the Republic of Albania	EMCDDA Director	2019
7.6.	Negotiation of working arrangement between the EMCDDA and the Ministry of Health of Ukraine	EMCDDA Director	2019
7.8.	Launch call for expression of interest for list of experts for the 'extended' Scientific Committee, as well as call for expression of interest for membership of the Scientific Committee for the mandate 2020–22	EMCDDA	2019
9.3.	Implement all outstanding recommendations from the IAS	EMCDDA	2019
8.	Prepare request to the Management Board to give the Director the mandate to negotiate a working arrangement with Kosovo*	EMCDDA	June 2019